172
Views
2
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Clinical Analysis and Risk Factors of Bronchiolitis Obliterans After Mycoplasma Pneumoniae Pneumonia

ORCID Icon, , , , &
Pages 4101-4108 | Published online: 28 Jul 2022

References

  • Rodriguez N, Mondeja B, Sardinas R, Vega D, Dumke R. First detection and characterization of macrolide-resistant Mycoplasma pneumoniae strains in Cuba. Int J Infect Dis. 2019;80:115–117. doi:10.1016/j.ijid.2018.12.018
  • Zhimin C, Yunxiao S, Shunying Z, et al. Expert consensus on diagnosis and treatment of mycoplasma pneumoniae pneumonia in children (2015 edition). Chin J Pract Pediatr. 2015;30(17):1304–1308.
  • Rodrigues E, Machado A, Silva S, Nunes B. Excess pneumonia and influenza hospitalizations associated with influenza epidemics in Portugal from season 1998/1999 to 2014/2015. Influenza Other Respir Viruses. 2018;12(1):153–160. doi:10.1111/irv.12501
  • Shimizu T. Inflammation-inducing factors of Mycoplasma pneumoniae. Front Microbiol. 2016;7:414. doi:10.3389/fmicb.2016.00414
  • Dai W, Wang H, Zhou Q, et al. An integrated respiratory microbial gene catalogue to better understand the microbial aetiology of Mycoplasma pneumoniae pneumonia. Gigascience. 2019;8(8). doi:10.1093/gigascience/giz093
  • Li Y, Cheng H, Wang H, Wang Y, Liu L. Composite factors, including Mycoplasmal pneumonia, hypersensitivity syndrome, and medicine, leading to bronchiolitis obliterans in a school-age child. Clin Pediatr. 2014;53(14):1409–1412. doi:10.1177/0009922814541808
  • Moonnumakal SP, Fan LL. Bronchiolitis obliterans in children. Curr Opin Pediatr. 2008;20(3):272–278. doi:10.1097/MOP.0b013e3282ff62e9
  • Chang-chong L, Yun-xiao S, Xu-zhuang S, Zhi-min C, Shun-ying Z. Guidelines for the management of community-acquired pneumonia in children (2013 Revised)(ii). Chin J Pediatr. 2013;51(11):856–862.
  • Board E. Diagnosis and treatment of bronchiolitis obliterans in children. Chin J Pediatr. 2012;50(10):743–745.
  • Colom AJ, Teper AM. Post-infectious bronchiolitis obliterans. Pediatr Pulmonol. 2019;54(2):212–219. doi:10.1002/ppul.24221
  • Chen J, Liu X, Du W, et al. Pulmonary function testing in pediatric pneumonia patients with wheezing younger than 3 years of age. Glob Pediatr Health. 2019;6:2333794X–19840357X.
  • Wang X, Liu C, Wang M, Zhang YI, Li H, Liu G. Clinical features of post-infectious bronchiolitis obliterans in patients undergoing long-term azithromycin treatment. Exp Ther Med. 2015;9(6):2379–2383. doi:10.3892/etm.2015.2418
  • Lee E, Young LY. Risk factors for the development of post-infectious bronchiolitis obliterans after Mycoplasma pneumoniae pneumonia in the era of increasing macrolide resistance. Respir Med. 2020;175:106209. doi:10.1016/j.rmed.2020.106209
  • Yu J. Postinfectious bronchiolitis obliterans in patients: lessons from bronchiolitis obliterans after lung transplantation and hematopoietic stem cell transplantation. Korean J Pediatr. 2015;58(12):459–465. doi:10.3345/kjp.2015.58.12.459
  • Yu X, Ma Y, Gao Y, You H. Epidemiology of adenovirus pneumonia and risk factors for bronchiolitis obliterans in children during an outbreak in Jilin, China. Front Pediatr. 2021;9:722885. doi:10.3389/fped.2021.722885
  • Colom AJ, Teper AM, Vollmer WM, Diette GB. Risk factors for the development of bronchiolitis obliterans in patients with bronchiolitis. Thorax. 2006;61(6):503–506. doi:10.1136/thx.2005.044909
  • Murtagh P, Giubergia V, Viale D, Bauer G, Pena HG. Lower respiratory infections by adenovirus in children. Clinical features and risk factors for bronchiolitis obliterans and mortality. Pediatr Pulmonol. 2009;44(5):450–456. doi:10.1002/ppul.20984
  • Liu TY, Lee WJ, Tsai CM, et al. Serum lactate dehydrogenase isoenzymes 4 plus 5 is a better biomarker than total lactate dehydrogenase for refractory Mycoplasma pneumoniae pneumonia in children. Pediatr Neonatol. 2018;59(5):501–506. doi:10.1016/j.pedneo.2017.12.008
  • Choi YJ, Jeon JH, Oh JW. Critical combination of initial markers for predicting refractory Mycoplasma pneumoniae pneumonia in children: a case control study. Respir Res. 2019;20(1):193. doi:10.1186/s12931-019-1152-5
  • Lu A, Wang C, Zhang X, Wang L, Qian L. Lactate dehydrogenase as a biomarker for prediction of refractory Mycoplasma pneumoniae Pneumonia in children. Respir Care. 2015;60(10):1469–1475. doi:10.4187/respcare.03920
  • Inamura N, Miyashita N, Hasegawa S, et al. Management of refractory Mycoplasma pneumoniae pneumonia: utility of measuring serum lactate dehydrogenase level. J Infect Chemother. 2014;20(4):270–273. doi:10.1016/j.jiac.2014.01.001
  • Wu PQ, Li X, Jiang WH, et al. Hypoxemia is an independent predictor of bronchiolitis obliterans following respiratory adenoviral infection in children. Springerplus. 2016;5(1):1622. doi:10.1186/s40064-016-3237-7
  • Zhao C, Liu J, Yang H, Xiang L, Zhao S. Mycoplasma pneumoniae-associated bronchiolitis obliterans following acute bronchiolitis. Sci Rep. 2017;7(1):8478. doi:10.1038/s41598-017-08861-7